Linking HIV Patients to Care and to Assessing the Feasibility and Acceptability of Rapid ART Initiation using BIC/FTC/TAF among HIV Positive Patients in China: A Randomized Control Trial

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000038711

Enrollment

Unknown

Registered

2020-09-29

Start date

2020-10-01

Completion date

Unknown

Last updated

2020-12-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV/AIDS

Interventions

the current regime rapid group:receive the current ART

the BIC/FTC/TAF rapid group:receive bictegravir/emtricitabine/tenofovir alafenamide

non-RAPID group:receive the current ART

Eligibility

Sex/Gender

Male

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: (1) 18 years of age or older; (2) Meet the diagnostic criteria for HIV-1 infection in the "Chinese AIDS Diagnosis and Treatment Guidelines (2018 )" (3) treatment naive; (4) be able to read and understand the consent form and give consent for participation.

Exclusion criteria

Exclusion criteria: (1) Severe opportunistic infections or tumors; (2) Transaminase exceeds the upper limit of normal by 3 times, and the creatinine clearance rate <=50umol/L; (3) Those who currently suffer from more serious chronic diseases, neurological and mental diseases that interfere with normal treatment and follow-up.

Design outcomes

Primary

Measure	Time frame
HIV RNA;CD4+ count;	—

Countries

China

Contacts

Public ContactLili Dai

Beijing Youan Hospital, Capital Medical University

lilydaier@163.com+86 13910983491

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026